I wrote before they will have about $15mm net cash at 12/31/08
if you then add the $40, we get $55
debt (20mm), op lease exp (1mm), cash bonuses (6mm), R&D (17mm), SG&A (3.5mm), then add back non cash exp, d&a .4mm, share base comp 2mm, change in op assets 3mm; but they also had large accrued liabilities for clinical trial expenses which will hit P&L at (5mm).
so about $2.6 in net cash... so basically the street is saying we don't value your bud nor your migraine made and we detract more because we think you will wastefully burn more;
but, I agree this stock is definitely a very good value